The Ubrelvy launch date was in the fourth quarter of 2019 [1]. This marked the availability of the medication following its approval by the U.S. Food and Drug Administration (FDA) [1].
When was Ubrelvy approved?
Ubrelvy received FDA approval on December 27, 2019 [1]. This approval allowed for its marketing and distribution in the United States.
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie [1]. The company is responsible for its production, marketing, and distribution.
What is Ubrelvy used for?
Ubrelvy is used for the acute treatment of migraine with or without aura in adults [1]. It is designed to provide relief from migraine symptoms when they occur, rather than for prevention.
How does Ubrelvy work?
Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the activity of CGRP, a molecule that plays a role in migraine. By inhibiting CGRP, Ubrelvy helps to alleviate the pain and other symptoms associated with migraines.
What are the side effects of Ubrelvy?
Common side effects of Ubrelvy can include nausea, tiredness, and dry mouth [1]. Patients considering the medication should discuss potential side effects with their healthcare provider.
What is the patent status for Ubrelvy?
Information regarding the specific patent status and expiration dates for Ubrelvy can be found on DrugPatentWatch.com [2]. Patents protect the exclusive rights of the drug manufacturer, influencing market competition and the potential for generic alternatives.
Are there alternatives to Ubrelvy for migraine treatment?
Yes, there are other treatment options for acute migraine. These include triptans, other CGRP receptor antagonists, and over-the-counter pain relievers [3]. The choice of treatment often depends on individual patient needs, medical history, and the severity of their migraines.
Sources:
[1] https://www.ubrelvy.com/
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360204